A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Cancer|Tumor, Solid|Nonsmall Cell Lung Cancer|Triple Negative Breast Cancer|Malignant Neoplasm|Metastatic Cancer|Advanced Solid Tumor
Interventions: DRUG: HMBD-002|DRUG: Pembrolizumab
Sponsor: Hummingbird Bioscience
Collaborators: Merck Sharp & Dohme LLC